Meeting
2018 ASCO Annual Meeting
Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.
Authors
William John Gradishar
Feinberg School of Medicine, Northwestern University, Chicago, IL
William John Gradishar , Mark E. Robson , Darl D Flake II, Lee Steven Schwartzberg , Priyanka Sharma , Hatem Hussein Soliman , Anthony Martin Magliocco , Krystal Brown , Saskia Wehnelt , Alexander Gutin , Ralf Kronenwett , Johnathan M. Lancaster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 36, 2018 (suppl; abstr 525)
DOI
10.1200/JCO.2018.36.15_suppl.525
Abstract #
525
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.
First Author: Anastasia Constantinidou
Poster
2024 ASCO Annual Meeting
Predicting epirubicin response in Danish patients with breast cancer.
First Author: Ida Kappel Buhl
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2022 ASCO Annual Meeting
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Mafalda Oliveira